What is the forecast for ELV stock?
Equity research analysts tracking Elevance Health, Inc. (ELV) maintain a consensus Buy rating, with average 12-month price targets clustering around $439.22 to $443.50 per share, and upper estimates reaching up to $498.00. Valuation frameworks incorporate multi-year membership dynamics across managed care programs, pharmacy benefit services expansion, medical cost ratio controls, and disciplined capital allocation strategies supporting long-term earnings growth.
Related FAQs
Elevance Health, Inc., a massive American health insurance and managed care titan, operated for many decades under the corporate name Anthem, Inc., and prior to that as WellPoint, Inc.
Yes, Elysian Bank offers a comprehensive mobile banking application that allows customers to manage their finances securely from their smartphones.
Yes, Elevance Health is the same company as the former Anthem, Inc. The company officially rebranded from Anthem, Inc.
Elevance Health Inc. (ELV) has seen a turbulent summer, with the stock closing July 31, 2026, at $375.84. This followed a peak of over $426 in mid-July, after which the stock experienced a correction.
Deciding whether to purchase shares of Elevance Health (ELV) requires evaluating its position as a major managed healthcare provider offering health insurance plans, commercial policies, and specialized healthcare services.
UnitedHealthcare and Anthem are both massive national insurers, and the "better" plan usually depends on the specific network available in your area.
Elevance Health, Inc. (formerly known as Anthem, Inc., trading under the ticker ELV) operates as a premier health benefits company in the United States, facing intense competition across managed care and health insurance sectors.
Elevance Health, Inc. (ELV) operates as a leading health benefits company and independent licensee of the Blue Cross Blue Shield Association, serving tens of millions of managed care members.
Elevance Health, Inc. (ELV) equity forecasts constructed by healthcare sector analysts incorporate multi-year operational projections across managed care and commercial health insurance segments.
Determining whether Elevance Health is a "good" investment depends on an investor’s portfolio objectives, as the stock is often viewed as a stable, large-cap utility-like play in the healthcare sector.
Elevance Health (ELV) is currently viewed favorably by market analysts, holding a consensus rating of "Buy". This positive outlook is supported by insights from a significant number of analysts who cover the company.
Gail Boudreaux resides in the United States, maintaining her primary household close to the corporate executive offices of Elevance Health, where she serves as the chief executive officer.
Executive compensation for the chief executive leadership guiding Entain plc (a major global sports betting, gaming, and interactive entertainment enterprise) reflects international corporate governance benchmarks.
The ticker symbol ELV historically represented Elevance Health, Inc. before its ticker transition, or relates to specific global securities.